Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-08
2008-07-08
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S311400, C548S316400
Reexamination Certificate
active
07396849
ABSTRACT:
Compounds of Formula 1where the variables have the meaning defined in the specification are agonists of alpha2adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2Band/or alpha2Cadrenergic receptors in preference over alpha2Aadrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.
REFERENCES:
patent: 4798843 (1989-01-01), Kruse
patent: 6124300 (2000-09-01), Rajagopalos et al.
patent: 6486187 (2002-11-01), Venet
patent: 0301603 (1989-02-01), None
patent: 0302603 (1989-02-01), None
patent: 1499485 (1979-02-01), None
patent: 6067368 (1994-03-01), None
patent: 2002097310 (2002-07-01), None
patent: 2002097312 (2002-07-01), None
patent: WO 99/28200 (1999-06-01), None
patent: WO 99/28300 (1999-06-01), None
patent: WO 01/00586 (2001-01-01), None
patent: WO 02/36162 (2002-05-01), None
patent: WO 03/099795 (2003-12-01), None
patent: WO2005/034849 (2005-04-01), None
patent: WO2005/034946 (2005-04-01), None
Trojanowski, John Q. “Alzheimer's Disease, Parkinson's Disease and Related Brain Disorders:Brief Overview for Patients and Caregivers,” internet article, Oct. 1999, found on http://pennhealth.com.
Ruffolo, Jr., “α-Adrenoreceptors”: Molecular Biology, Biochemistry and Pharmacology, (Progress in Basic and Clinical Pharmacology series, Karger, 1991).
Messier et al, High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin Receptors in Living Mammalian Cells, 1995, 76, pp. 308-311.
Conklin et al, “Substitution of three amino acids switches receptor specificity of Gqα to that of G1α”, 1993, Nature 363: 274-6.
Dirig et al, “Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli”,J. Neurosci. Methods, 1997, 76: 183-191.
Hargreaves et al, “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia”, 1988, Pain 32: 77-88.
Dixon, W.J., “Efficient Analysis of Experimental Observations”, Ann. Rev. Pharmacol. Toxicol., 1980, 20: 441-462.
Minami et al, “Allodynia evoked by intrathecal administration of prostaglandin E2to conscious mice”, 1994, 57 Pain, 217-223.
Chow Ken
Donello John E.
Garst Michael E.
Gil Daniel W.
Heidelbaugh Todd M.
Allergan Inc.
Allergan, Inc.
Coppins Janet L
Saeed Kamal
Voet Martin
LandOfFree
4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2786187